Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H2 2017’, provides in depth analysis on Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Cardiovascular under development targeting Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Exelixis Inc

Ignyta Inc

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Takeda Pharmaceutical Co Ltd

Tolero Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Overview 8

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 16

Products under Development by Universities/Institutes 23

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Assessment 25

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 27

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Companies Involved in Therapeutics Development 29

Astellas Pharma Inc 29

BerGenBio ASA 29

Betta Pharmaceuticals Co Ltd 30

Celldex Therapeutics Inc 30

Daiichi Sankyo Co Ltd 31

Exelixis Inc 31

Ignyta Inc 33

Les Laboratoires Servier SAS 33

Mirati Therapeutics Inc 34

Ono Pharmaceutical Co Ltd 34

Oribase Pharma 35

Qurient Co Ltd 35

Rigel Pharmaceuticals Inc 36

SignalChem Lifesciences Corp 36

Takeda Pharmaceutical Co Ltd 36

Tolero Pharmaceuticals Inc 37

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Drug Profiles 38

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

BGB-002 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

BGB-149 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

BGB-324 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

BGB-601 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

BPI-9016 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

cabozantinib s-malate - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CT-053 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

CT-413 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

DS-1205 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Fusion Protein to Inhibit Axl Tyrosine kinase for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

gilteritinib fumarate - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

glesatinib - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

HOPE-777 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

ONO-7475 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Q-701 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

R-916562 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

RXDX-106 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

S-49076 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

sitravatinib - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

SLC-0211 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Small Molecule to Inhibit AXL for Oncology - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

TP-0903 - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Dormant Products 103

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Discontinued Products 105

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Product Development Milestones 106

Featured News & Press Releases 106

Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting 106

Nov 01, 2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting 106

Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer 107

Oct 16, 2017: Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma 107

Oct 16, 2017: Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma 108

Oct 16, 2017: Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma 109

Oct 12, 2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma 110

Oct 11, 2017: U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia 110

Oct 05, 2017: Tolero Pharma To Provide Update On TP-0903 At 9th International Conference On Leukemia And Hematologic Oncology 111

Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting 111

Sep 28, 2017: BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer 112

Sep 14, 2017: Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer 112

Sep 09, 2017: Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 114

Sep 08, 2017: Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults 115

Sep 06, 2017: Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress 116

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15

Number of Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 22

Number of Products under Investigation by Universities/Institutes, H2 2017 23

Products under Investigation by Universities/Institutes, H2 2017 24

Number of Products by Stage and Mechanism of Actions, H2 2017 25

Number of Products by Stage and Route of Administration, H2 2017 26

Number of Products by Stage and Molecule Type, H2 2017 28

Pipeline by Astellas Pharma Inc, H2 2017 29

Pipeline by BerGenBio ASA, H2 2017 30

Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017 30

Pipeline by Celldex Therapeutics Inc, H2 2017 31

Pipeline by Daiichi Sankyo Co Ltd, H2 2017 31

Pipeline by Exelixis Inc, H2 2017 32

Pipeline by Ignyta Inc, H2 2017 33

Pipeline by Les Laboratoires Servier SAS, H2 2017 33

Pipeline by Mirati Therapeutics Inc, H2 2017 34

Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 35

Pipeline by Oribase Pharma, H2 2017 35

Pipeline by Qurient Co Ltd, H2 2017 35

Pipeline by Rigel Pharmaceuticals Inc, H2 2017 36

Pipeline by SignalChem Lifesciences Corp, H2 2017 36

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 37

Pipeline by Tolero Pharmaceuticals Inc, H2 2017 37

Dormant Products, H2 2017 103

Dormant Products, H2 2017 (Contd..1), H2 2017 104

Discontinued Products, H2 2017 105

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 25

Number of Products by Stage and Route of Administration, H2 2017 26

Number of Products by Molecule Types, H2 2017 27

Number of Products by Stage and Molecule Types, H2 2017 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports